Ralliant (NYSE:RAL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Ralliant (NYSE:RAL) from a hold rating to a strong-buy rating in a research note issued to investors on Monday.

A number of other brokerages have also weighed in on RAL. TD Cowen upped their target price on shares of Ralliant from $70.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Morgan Stanley lifted their price target on shares of Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a report on Tuesday, June 23rd. Evercore assumed coverage on shares of Ralliant in a research note on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 price target on the stock. Oppenheimer boosted their price target on shares of Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 13th. Finally, BMO Capital Markets began coverage on shares of Ralliant in a report on Monday, July 20th. They set a “market perform” rating and a $78.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Ralliant presently has an average rating of “Moderate Buy” and a consensus price target of $75.70.

Ralliant Stock Down 0.8%

Shares of RAL opened at $66.38 on Monday. The business’s 50 day moving average is $67.45 and its 200 day moving average is $54.63. The company has a current ratio of 1.52, a quick ratio of 1.00 and a debt-to-equity ratio of 0.75. Ralliant has a 12-month low of $37.27 and a 12-month high of $75.41. The company has a market capitalization of $7.34 billion, a PE ratio of -6.12, a price-to-earnings-growth ratio of 2.49 and a beta of 1.60.

Ralliant (NYSE:RAL) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.05. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.The business had revenue of $567.80 million during the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Research analysts expect that Ralliant will post 2.87 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 8th. Ralliant’s dividend payout ratio is currently -1.84%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Danske Bank A S purchased a new stake in Ralliant during the fourth quarter valued at $25,000. V Square Quantitative Management LLC bought a new stake in shares of Ralliant in the 4th quarter worth about $26,000. Allworth Financial LP increased its holdings in shares of Ralliant by 134.4% in the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after buying an additional 293 shares during the last quarter. Palisade Asset Management LLC purchased a new stake in shares of Ralliant during the 3rd quarter valued at about $26,000. Finally, BOKF NA purchased a new stake in shares of Ralliant during the 3rd quarter valued at about $29,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.